The aim of this review is to provide a discussion of the diagnostic evaluation of biochemical recurrence following radical prostatectomy (RP) and an overview of the postoperative hormonal treatment (HT) options. As no randomized trials in the clinical setting of postoperative prostatespecific antigen recurrence have been reported, there is no conclusive evidence that HT after RP will prolong survival or reduce morbidity. Non-traditional approaches, such as intermittent androgen deprivation, non-steroidal anti-androgens and combination of finasteride and nonsteroidal anti-androgen, are investigated and may be acceptable options. Combinations of HT with radiotherapy and/or chemotherapy for treatment of recurrent prostate cancer are under study.
Introduction
Despite the improved outcome of radical prostatectomy (RP) in many men with prostate cancer (PCa) in recent years, a number of men still experience prostate-specific antigen (PSA) recurrence and are at risk for the development of metastasis and PCa-specific mortality. Given the increasing numbers of relatively young patients with postoperative PSA recurrence (PSAR), there is a need for treatment strategies that improve clinical outcomes and preserve quality of life (QOL). However, currently no consensus exists on how patients with PSAR after RP should be treated. Treatment options are active surveillance, the use of postoperative radiation therapy (RT), hormonal therapy (HT) and even early chemohormonal therapy. Survival advantage of adjuvant HT after RP has been proven only in patients with positive lymph node PCa in a single randomized trial. 1, 2 To date, the role of adjuvant HT after RP and the optimal timing and duration of HT remain controversial. The aim of this review is to discuss the diagnostic evaluation of local and systemic recurrence and to provide an overview of the HT options for men with postoperative PSAR.
PSA recurrence after RP

Definition of biochemical recurrence following RP
The exact level of serum PSA that defines recurrent cancer following RP is debatable. Amling et al. 3 found that a serum PSA value 40.4 ng ml À1 was the most appropriate cutoff point to initiate treatment. However, Freedland et al. found support in the more conventional cutoff point of 40.2 ng ml À1 . 4 Recently, the American Urology Association Prostate Guidelines and the European Association of Urology Guidelines recommend defining biochemical recurrence following RP as an initial serum PSA X0.2 ng ml À1 with a second confirmatory level of PSA 40.2 ng ml À1 . 5, 6 Natural history of biochemical recurrence Between 25 and 40% of men undergoing RP will have PSA relapse after a follow-up period of about 10 years. 7 Although this figure could be lowered today, the clinical significance of biochemical recurrence still remains unclear. The natural history in the average men who present with postoperative PSAR is long, but in some men, progression can be rapid. In one series including 304 patients with postoperative PSAR who did not receive HT until the time of metastasis, the median time to metastasis was 8 years. The median time from metastasis to death was 5 years. 8 In a cohort of 1746 men undergoing RP, the natural history of biochemical recurrence was examined over a 20-year period beginning in 1983. Of these men, 17% had PSAR. The 5-, 10-and 15-year PCa-specific mortality in patients with PSAR was 1, 5 and 11%, respectively. The risk of dying from PCa within 15 years of the first rise in PSA level was only 32%. This is similar to the percentage of patients dying from other causes (33%). 9 Of 4 708 men treated with RP alone, 3-38% of the patients had highrisk PCa depending on the definition used. More than half of these are cured by surgery alone (5-year relapsefree probability, 49-80%) and few are likely to die of their cancer within 10 years. 10 
Diagnostic evaluation
Once PSAR after RP has been diagnosed, it is of major importance to determine whether the recurrence has developed at local or distant sites because management of PSA failure is dependent on the site of recurrence. In general, digital rectal examination is not useful in men with undetectable or very low PSA levels. Conventional diagnostic imaging, such as computed tomography (CT) and bone scintigraphy, very often are not able to detect whether the recurrence has developed at local and/or distant (systemic) sites. PSA velocity and the slope of PSA increase seem to be the most important predictors of distant metastases. 11 Deliveliotis et al. 12 recently reported that transrectal ultrasound-guided biopsy is an efficient tool in detecting local recurrence after RP and should be offered to all patients with biochemical relapse and absence of metastatic disease, irrespective of the level of PSA. Tamsel et al. 13 reported good results of targeted biopsies of hypervascular lesions at power Doppler ultrasound. The sensitivity and specificity of transrectal ultrasound alone in detecting recurrent tumour were 93 and 67%, respectively, with a positive predictive value of 93% and a negative predictive value of 67%. Transrectal ultrasound combined with power Doppler ultrasound had a sensitivity and specificity of 93 and 100%, respectively, with a positive predictive value and a negative predictive value of 100 and 75%, respectively. Probably, in routine practice, prostatic fossa biopsy should be avoided in patients with both or either normal digital rectal examination or transrectal ultrasound findings when the PSA level is less than 0.5 ng ml À1 .
14 Sciarra et al. 15 recently showed that combined magnetic resonance (MR) spectroscopy and dynamic contrastenhanced MR imaging are an accurate method to identify local PCAR in patients with biochemical progression after RP. Macrophage-specific MR contrast agents allow the detection of small and otherwise undetectable lymph node metastases in patients with PCa. In patients with a suspicion of a recurrence, this technique may show metastatic deposits in lymph nodes of normal size. Identifying small pathologic lymph nodes probably will facilitate a more appropriate use of sophisticated RT, that is precise intensity-modulated radiotherapy can be performed. This ultimately may result in an increased dose on malignant nodes and a decreased dose, with reduced side effects on normal tissues. 16 MR imaging with endorectal coil, combined with dynamic contrast-enhanced imaging, seems to have a higher sensitivity and specificity compared with MR imaging alone in detecting local recurrences after RP. 17 The application of MR imaging and nuclear medicine (positron emission/CT (PET/CT) with new tracers like 11 C or 18 F-choline and acetate) might offer a better assessment of recurrent PCa. 18 The detection rate is directly correlated to the PSA value at the time of study, with detection rates between 36 and 60% at levels below 1 and a sensitivity of approximately 80% for values up to 2.5 ng ml À1 . [19] [20] [21] [22] With the limitation that there are up to now no large prospective trials using choline PET/CT, there is evidence that it can be recommended at PSA values o 2.5 ng ml À1 20 but is not sensitive enough below 0.5 ng ml À1 . Other PET tracers have been used, among which 11 C-acetate seems to be the most promising, addressing the increased lipid synthesis within PCa. 23 Results seem to be comparable with those with choline; however; larger studies are lacking.
11
C choline PET/CT is an accurate diagnostic tool for the detection of lymph node metastases of recurrent PCa. The low negative predictive value seems to depend on the limited capability to detect microscopic metastatic deposits. Yet, the high positive predictive value, even with low PSA values, provides a basis for further treatment decisions. 24 The ProstaScint imaging (indium-111 capromab pendetide immunoscintigraphy) using a radiolabelled monoclonal antibody targeting the prostate-specific membrane antigen might represent a valuable diagnostic test with an accuracy of up to 81% to detect the site of PSAR. With a diagnostic yield of 60-80% independent of the PSA serum level, it might help select men for subsequent clinical management according to the location of positive sites. Raj et al. 25 examined the utility of this imaging test in 255 men with a serum PSA recurrence p4.0 ng ml À1 following RP. Uptake was detected in 72% throughout the range of postoperative PSA serum levels (0.1-4.0 ng ml
À1
). Approximately 31, 43 and 29% of patients showed local uptake, regional uptake and distant uptake, respectively. Studies with long-term follow-up are needed to determine if isolated uptake in the prostatic fossa predicts a favourable long-term outcome. Integrated single-photon emission tomography/CT imaging is highly recommended for ProstaScint hybrid imaging, as also with this potentially highly specific tracer, a significant amount of unspecific uptake in the bowl and other tissue has been seen. A further problematic is that the imaging protocol goes over 7 days, making this not an easy approach for outpatients compared with abovementioned PET protocols that are finished within 30-60 min after tracer injection. 26 ProstaScint has received FDA approval, however, there is still controversy on its value.
Local and systemic failure
Moderately differentiated primary tumours, late PSA relapse and slow rising PSA are suggestive of local failure. Local failure following RP is predicted with an 80% probability by PSA relapse 43 years after RP, PSADT X11 months, Gleason score p6 and stage ppT3a pN0, pTx R1 (R1 ¼ positive surgical margin). Local recurrences are best treated by salvage RT. 27 If the patients have poorly differentiated tumours, early PSA relapse and quickly rising PSA systemic disease are assumed to be present. Systemic failure following RP is predicted with 480% accuracy by PSA relapse o1 year, PSADT of 4-6 months, Gleason score 8-10 and stage pT3b, pTxpN1. There is some evidence that early HT may be of benefit in delaying progression PSA recurrence and hormonal management after RP HV Poppel et al and possibly achieving a survival benefit.
1,2,27 It is not known, however, how many patients could still benefit from salvage RT in this setting.
Side effects of HT
The transient elevation of testosterone (surge) causing flare that occurs after initial administration of luteinizing hormone-releasing hormone agonists may be prevented by a 4-to 6-week administration of an anti-androgen. The side effects of luteinizing hormone-releasing hormone agonists are listed in Table 1. 28-31 Continuous androgen deprivation therapy (ADT) increases the prevalence of osteoporosis, 31 metabolic syndrome, 29 diabetes and cardiovascular diseases. 30 Therefore, decisions on the immediate introduction of ADT after PSAR should take into account patient's life expectancy and the long-term complications of ADT. Non-steroidal antiandrogens have a lower risk of side effects than castration in terms of maintenance of sexual interest, physical ability and bone mineral density. The most frequent side effects induced are mild-to-moderate gynaecomastia and breast pain. There are no direct comparisons between the three non-steroidal anti-androgens in terms of QOL, but available evidence suggests that bicalutamide has a more favourable safety and tolerability profile than flutamide and nilutamide. The steroidal anti-androgen cyproterone acetate is associated with loss of libido, erectile dysfunction and cardiovascular risk, and there have been occasional reports of liver failure. 32 Small studies showed that intermittent androgen deprivation (IAD) may have an advantage over continuous androgen deprivation (CAD) with regard to depression and cognitive function, sexual function, bone health and overall QOL because of the recovery of testosterone levels and reduced toxicity during offtreatment periods. 33 During minimal androgen blockade, the testosterone levels are preserved within the normal range to provide a satisfactory sexual function and QOL. 27 The effect of intermittent ADT on diabetes and cardiovascular risk is unknown.
Adjuvant HT after RP
In the absence of randomized controlled trials for postoperative PSAR, we must rely on retrospective data or extrapolate data from other clinical settings, such as men with metastatic disease or locally advanced nonmetastatic disease. Whether these data are relevant to men with rising postoperative PSA levels is uncertain. Two randomized studies compared immediate HT (after diagnosis) with deferred HT (on progression) in patients with PCa. The Medical Research Council study in locally advanced or asymptomatic metastatic PCa and the European Organisation for Research and Treatment study in newly diagnosed PCa (T0-4N0M0) illustrate that although immediate HT after diagnosis can delay disease progression in men with PCa, it does not necessarily result in an improved cancer-specific survival (CSS). 34, 35 Postoperative HT in clinical settings other than PSAR The effect of adjuvant HT after RP obtained in randomized studies is presented in Table 2 . Survival advantage of immediate (adjuvant) ADT after RP has only been proven in patients with positive lymph node PCa in a single randomized study.
1,2 The updated results of this multicentre Eastern Cooperative Oncology Group study after a median follow-up of 11.9 years show a significant improvement in overall survival (OS), CSS and progression-free survival in lymph-node-positive (N þ ) patients treated with immediate ADT. 2 The table shows that flutamide 750 mg could improve progressionfree survival but did not result in improvement in OS when given as an adjuvant to RP. 36 Adjuvant bicalutamide 150 mg could decrease progression in men with locally advanced PCa, but did not result in an OS benefit. 37 Several retrospective analyses from the Mayo Clinic showed that adjuvant HT after RP had a positive effect on time to progression and cancer death in patients with pT3b and N þ PCa. [38] [39] [40] However, a recent large series from the Mayo Clinic with a median follow-up of 10.3 years showed that adjuvant HT in patients with surgically managed N þ PCa decreased the risk of biochemical recurrence and local recurrence but did not 41 A recent retrospective study with a median follow-up of 5.2 years showed that immediate and delayed HT (at PSA recurrence) in patients with surgically managed N þ PCa provided similar outcomes. 42 An observational study showed that deferring immediate ADT in men with positive lymph nodes after RP may not significantly compromise survival. There was no statistically significant difference in survival with 90, 150, 180 and 365 days as the definition of adjuvant ADT. These results should be validated in a prospective study. 43 To date, no recommendations can be made regarding the optimal timing and duration of adjuvant HT after RP. A study that has been started recently is RADICALS. This is a large randomized controlled study sponsored by the Medical Research Council addressing the timing of RT (adjuvant vs early salvage) and the duration of HT (none vs short-term vs long-term) used in conjunction with postoperative RT. Primary outcome measure will be CSS, and secondary outcome measures will include OS, androgen deprivation outside the protocol and reported treatment toxicity. The study also aims to assess the longterm effect of RT after RP on sexual, urinary and bowel function and the long-term effect of androgen deprivation on sexual function and overall QOL. Therefore, patients will be asked to complete four short questionnaires. These assessments will be done only at baseline, and at 5 and 10 years. 44 Postoperative HT for PSA recurrence Although HT remains the standard treatment for advanced PCa, its role in the treatment of non-metastatic PCa recurrences is controversial because it is associated with considerable costs and side effects. Clinicians treating men with PSAR face the difficult question on who should receive HT and at what time point. Modalities of HT for the group of patients with postoperative PSAR are debated.
Androgen deprivation. Although patients with postoperative PSAR frequently undergo ADT before evidence of metastatic disease, the benefit of this approach is uncertain. Table 3 presents an overview of three retrospective studies, including patients with postoperative PSAR who received HT after RP. A retrospective study including 1352 patients with postoperative PSAR showed no significant difference in the time to clinical metastases with early ADT (after PSAR but before clinical metastases) vs delayed ADT (at the time of clinical metastases). However, upon risk stratification, early ADT could delay the time to clinical metastases in high-risk patients with a Gleason score47 and/or a PSADTp12 months. ADT had no overall impact on PCa-specific mortality. 45 A recent retrospective study from the Mayo Clinic showed that adjuvant ADT (within 90 days of surgery) slightly improved the CSS and PSA recurrence and hormonal management after RP HV Poppel et al systemic progression-free survival after RP in a large group of high-risk patients with PCa. However, the survival advantage was lost when ADT was delivered farther in the disease process, at the time of PSAR or systemic progression. It should be emphasized that there was no OS advantage (83% for both groups) and that the difference in CSS and systemic progression-free survival was only 3 and 5%, respectively. 46 In a recent retrospective study including 422 patients with postoperative PSAR, 123 developed distant metastasis, of whom 91 patients with complete data received deferred ADT at the time of documented metastasis after RP. The authors concluded that patients when closely followed after PSAR may have an excellent response to deferred ADT and a long survival with a median failure time of 168 months from RP to death. 47 We should take into account that these three studies are limited by their retrospective design and also in assessing the side effects of long-term ADT. Evidence from well-designed, prospective randomized studies is needed before advocating the use of early HT in clinical practice.
Anti-androgens. Low-dose flutamide 250 mg daily is currently being investigated in men with PSAR. Bicalutamide 150 mg daily has not yet been studied in this clinical setting. 48 Intermittent androgen deprivation. Intermittent androgen deprivation has been examined as a potential alternative to CAD to delay the time to androgen independence and hormone-refractory disease, to minimize the side effects and to reduce the costs of prolonged therapy. Recently, the Cochrane Collaboration revealed that there are no long-term data of large-scale randomized controlled trials available that prove the superiority of IAD over CAD in terms of its effect on survival. Limited information suggests that IAD may result in a slight reduction of adverse effects. Overall, IAD was as effective as CAD for potency, but was superior during the off-treatment periods of cycles (96%). 49 A randomized controlled phase III trial (EC507) evaluating the outcome of IAD and CAD in patients with postoperative PSAR is currently being undertaken in Europe. All patients initially receive ADT with leuprorelin 3-month depot for 6 months plus cyproterone acetate for the first 4 weeks. They are then randomized to receive either IAD or CAD. The on-treatment period is 6 months and IAD restarts during the off-treatment period when the PSA level rises to 43.0 ng ml
À1
. Bone loss is worse with CAD therapy. IAD is associated with improvements in the QOL. Interim analyses to date suggest that progressionfree survival is similar with IAD and CAD therapy. 33 In the meantime, IAD remains attractive to selected, closely monitored and well-informed patients with postoperative PSAR. This study and another study examining intermittent HT (flutamide and leuprolide acetate) in this setting are indicated in Table 4 .
Minimal androgen blockade. In a phase II study, the combination of the 5-a-reductase inhibitor, finasteride (10 mg daily), and the non-steroidal androgen, flutamide (250 mg daily), was relatively well tolerated and showed a moderate efficacy in men with PSAR following definitive therapy. 50 HT after RP combined with RT and/or chemotherapy. Salvage RT may potentially cure patients with recurrent PCa after RP. A retrospective study revealed that selected patients with high-grade disease and/or rapid PSADT, in whom metastatic disease was assumed traditionally, may have long-term biochemical control after salvage RT. 51 More recently, a nomogram has been developed to predict the outcome of salvage RT for biochemical recurrence following RP. 52 A recent retrospective study showed that salvage RT (n ¼ 160) given within 2 years of biochemical recurrence vs observation (n ¼ 397) was associated with a threefold improvement in CSS among men with PSADT o 6 months, regardless of surgical margin status or Gleason score. The addition of HT to salvage RT (n ¼ 78) was not associated with any additional increase in CSS. 53 A recent phase II trial including 74 patients with postoperative PSAR showed that combined treatment with salvage RT plus 2 years' maximum androgen blockade (castration þ oral anti-androgen) had relatively minor long-term effects on QOL. 54 However, more efficacy data are needed and the potential increase in side effects should be considered when combining therapies. A randomized controlled phase III study from the Radiation Therapy Oncology Group (RTOG-9061) comparing RT plus placebo with the combination of RT plus bicalutamide 150 mg daily in the postoperative setting is completed and outcome data are currently undergoing statistical analysis. Results are eagerly awaited.
Currently, there is no indication for chemotherapy in patients with PSA recurrence only. Chemotherapy should be considered as a treatment option for patients with hormone refractory PCa, but the time point at which to initiate a cytotoxic regime remains controversial. 6 The last year's chemotherapy is, in clinical trials, combined more frequently with HT and/or RT in the locally advanced setting. Several ongoing and recruiting trials with patients receiving HT alone after RP or receiving HT combined with RT and/or chemotherapy are listed in Table 4 .
Conclusions
The natural history of patients with PSA recurrent cancer is long but variable, and identification of patients who are at high risk for progression remains difficult. Several prognostic factors have been studied and rapid PSADT is associated with a high risk for progression. The diagnostic evaluation of PSA recurrence is evolving. The precise role of additional HT in the treatment of postoperative PSAR is unknown, as no randomized trials in this particular clinical setting have been reported. Although studies have shown a modest survival benefit in high-risk patients who undergo early ADT after RP, there is no convincing evidence that it prolongs OS or reduces morbidity. Moreover, early ADT may unnecessarily expose many patients with PCa to the side effects of therapy. The current data are insufficient to make PSA recurrence and hormonal management after RP HV Poppel et al recommendation for early ADT in these patients. Non-traditional approaches, such as IAD, non-steroidal anti-androgens and the combination of finasteride with a non-steroidal anti-androgen, are investigated and may be acceptable options. The potential benefit of adjuvant HT after RP has to be balanced against the side effects of therapy and the knowledge that PCa after HT may progress to hormone refractory disease and limit subsequent treatment options. Future prospective studies are needed to further elucidate the optimal type and timing of HT for postoperative PSAR and to evaluate the potential survival benefit. Combinations of HT with RT and/or chemotherapy are currently under study. In the meantime, it is recommended to opt for an individual tailored therapy that takes into account the patients' prognostic factor profile (rapid PSADT), his preferences and his ability to comply with treatment. PSA recurrence and hormonal management after RP HV Poppel et al
